FDA Recalls Veklury Injection Vials for Presence of Glass Particles
Gilead Sciences recalls 105,000 vials of Veklury (remdesivir) for injection nationwide because glass particles are present in the medication.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this as a Class I drug recall, which by definition scores no lower than 4. No deaths or reported illnesses are mentioned in the source text.
Plain-English summary
Gilead Sciences, Inc. is recalling Veklury (remdesivir) for injection, 100 mg per vial. The recall affects 105,000 vials with Lot number 47035CFA and expiration date November 2025, distributed nationwide in the United States.
The recall is due to the presence of glass particles in the vials. The FDA has classified this as a Class I recall, the most serious type of recall classification.
Healthcare providers and facilities that have received affected vials should cease distribution and use immediately.
The recalled product
- Product
- VEKLURY (REMDESIVIR)
- Brand
- VEKLURY
- Manufacturer
- Gilead Sciences, Inc.
- Category
- Drug — Intravenous Injection
- Hazard
- glass-particles
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 47035CFA
- Exp. 11/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · VEKLURY
- SevereVeklury (Remdesivir) Drug Vials Recalled for Glass Particulate Matter
FDA (Drugs) · 2022-01-05
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27